Global News | Astellas

Month Year

Mar 25, 2016

Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer

Read more
Mar 22, 2016

POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING ROMOSOZUMAB IN MEN WITH OSTEOPOROSIS

BRIDGE Study Met Primary and All Secondary Endpoints

TOKYO (March 22, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, “Amgen Astellas”) and Astellas Pharma Inc....

Read more
Mar 16, 2016

Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women

- First time for a Pharmaceutical Company to be named to both Diversity Management Selection 100 and Nadeshiko Brand -

Read more
Mar 4, 2016

Astellas Announces Personnel Changes

Read more
Mar 2, 2016

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Mar 1, 2016

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Mar 1, 2016

Astellas Announces Personnel Changes and Organizational Change

Read more
Mar 1, 2016

Astellas Announces Management Structure Change

Read more
Feb 29, 2016

Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan

Read more
Feb 24, 2016

Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan

Tokyo, February 24, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a new drug application for a guanylate...

Read more
Feb 22, 2016

FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide

Read more
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries

Read more
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidaries

Read more
Feb 1, 2016

Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa

Tokyo and Miyagi, February 1st, 2016 - Astellas Pharma Inc. (TSE : 4503, President and CEO : Yoshihiko Hatanaka, “Astellas”) and CLINO Corporation (President : Noriaki Satake, “CLINO”)...

Read more
Jan 29, 2016

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Jan 23, 2016

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN OSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture Through 12 and 24 Months

Read more
Jan 22, 2016

REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL

Important Milestone for Certain Japanese Patients With Uncontrolled LDL Cholesterol

Read more
Jan 22, 2016

Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - ASTELLAS IS COMMITTED TO TRANSACTION, ACQUISITION OF OCATA IS A STRATEGIC PRIORITY -

Tokyo and Massachusetts, January 22, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:...

Read more
Jan 7, 2016

Extension of agreement on Telmisartan (Micardis® family)

Read more
Dec 18, 2015

Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics

Tokyo and Massachusetts, December 18, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:...

Read more
Dec 10, 2015

Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy

Houston and Tokyo, December 10, 2015 - Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM, “Bellicum”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that Agensys, Inc....

Read more
Dec 2, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Dec 1, 2015

Astellas Announces Personnel Change

Read more
Dec 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Nov 30, 2015

Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan

Read more
Nov 20, 2015

Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics

Tokyo, November 20, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has commenced, through its indirect wholly-owned...

Read more
Nov 18, 2015

Presentation for Astellas to Acquire Ocata Therapeutics

Astellas added minor revisions into the presentation for Astellas to acquire Ocata Therapeutics which was disclosed on November 10th, 2015. Presentation for Astellas to Acquire Ocata Therapeutics...

Read more
Nov 13, 2015

Named to 2015 Climate Disclosure Leadership Index -Recognized for perfect disclosure score for climate change information -

Tokyo, November 13, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been named for the first time to the CDP1) Japan 500 Climate...

Read more
Nov 10, 2015

The 2nd Year Results of C-OPERA, a Study of Anti-TNF-alpha Antibody Certolizumab Pegol, Announced at 2015 ACR/ARHP Annual Meeting

- The Clinical benefit of initial 1-year CZP treatment was maintained after discontinuation up to another 1-year -

Read more
Nov 10, 2015

Acquisition of Ocata Therapeutics

New Step Forward in Ophthalmology with Cell Therapy Approach

Read more
Oct 30, 2015

Astellas Concludes Agreement with MicroBiopharm Japan on Transfer of Kiyosu Plant Business

Read more
Oct 28, 2015

Astellas Announces Acquisition of Own Shares

Read more
Oct 28, 2015

Astellas Initiates Phase 3 Registration Trial of gilterritnib (ASP2215) in Relapsed of Refractory Acute Myeloid Leukemia Patients

Read more
Oct 9, 2015

Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease

Hershey, PA & Rockville, MD and Tokyo, Japan, October 9, 2015 – Immunomic Therapeutics, Inc. (“Immunomic Therapeutics”), a company developing next generation vaccines based on the LAMP-vax...

Read more
Oct 5, 2015

Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund

Read more
Sep 30, 2015

Submission of a Supplemental New Drug Application for ASP1585 Granule,a Treatment for Hyperphosphatemia, in Japan

Tokyo, September 30, 2015 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a supplemental new drug application for...

Read more
Sep 30, 2015

Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain

Tokyo and North Brunswick, N.J., Sept 30th, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Chromocell Corporation (CEO: Christian Kopfli,...

Read more
Sep 18, 2015

Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Fifth Consecutive Year

Read more
Sep 17, 2015

Astellas Supports Relief Efforts Following Typhoon in Eastern and Northern Japan

Read more
Sep 8, 2015

Astellas Named to FTSE4Good Sustainability Index for the Fourth Consecutive Year

Read more
Sep 7, 2015

Astellas donates ambulances on First-Aid Day (September 9)

-45th donation since 1970, totaling 234 ambulances

Read more
Aug 27, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Aug 20, 2015

Astellas Announces Changes in Personnel and Sales and Marketing Structure in Japan

Read more
Jul 31, 2015

Astellas Establishes New Real World Informatics and Analytics Function

Tokyo, Japan, July 31, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, collectively with its affiliates, hereinafter called “Astellas”) announced the launch of the Real...

Read more
Jul 31, 2015

Astellas Announces Acquisition of Own Shares

Read more
Jul 30, 2015

Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections

NORTHBROOK, Ill., July 30, 2015 – Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole,...

Read more
Jul 23, 2015

Astellas Initiates Collaborative Research with National Institute of Advanced Industrial Science and Technology by Utilizing Highly Advanced IT Drug-Discovery Technologies

- Aiming for early discovery of compounds in the areas of Ophthalmology and Nephrology by merging approximately 10,000 of protein-ligand complex structural information and highly advanced IT drug-discovery technologies -

Read more
Jul 22, 2015

“Cell therapy using human iPSC-derived renal progenitors ameliorates acute kidney injury in mice” published in “Stem Cells Translational Medicine” on line

Read more
Jul 16, 2015

The Netherlands Decorates Masafumi Nogimori, Representative Director and Chairman of Astellas with "Officer in the Order of Oranje-Nassau" Royal Decoration

Read more
Jul 13, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more

Show per page

Choose Language

News